Advertisement

Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

      Background: ALRN-6924 is a cell-permeating, stabilized alpha-helical peptide that binds with high affinity to endogenous p53 inhibitors MDM2 and MDMX. Treatment with ALRN-6924 increases intracellular p53 levels and initiates its transcriptional activity, leading to cell cycle arrest. This effect is limited to cells with wild-type, functional p53; therefore, for patients with tumors harboring mutated P53, pre-treatment with ALRN-6924 may selectively induce cell cycle arrest in normal cells allowing chemotherapy to selectively target cancer cells which are actively cycling.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect